Chemical inhibitors of D330012F22Rik can interfere with various signaling pathways to reduce the activity of this protein. Triciribine directly targets the AKT signaling pathway, where it acts to inhibit AKT, a kinase that plays a pivotal role in various cellular processes, including metabolism, proliferation, cell survival, growth, and angiogenesis. Since D330012F22Rik is potentially involved in AKT pathway signaling, the inhibition of AKT by Triciribine would lead to a reduction in D330012F22Rik activity. Similarly, Rapamycin is an inhibitor of the mTOR pathway, a crucial regulator of cell growth and protein synthesis. By inhibiting mTOR, Rapamycin can suppress the downstream effects that may include the functional activities of D330012F22Rik. Wortmannin and LY294002 both act on the PI3K/AKT pathway by inhibiting PI3K, leading to a decrease in AKT phosphorylation and subsequent activity, which could result in reduced activity of D330012F22Rik if it operates within this pathway.
In addition to these inhibitors, PD98059 and U0126 target the MEK enzymes within the MAPK/ERK pathway, another critical pathway for cell proliferation and survival. Inhibition of MEK could reduce D330012F22Rik activity if it is linked to the MAPK/ERK signaling pathway. Similarly, SB203580, which inhibits p38 MAPK, could decrease the activity of D330012F22Rik by interfering with the p38 MAPK signaling cascade. The JNK pathway, which can be inhibited by SP600125, also plays a role in cellular stress responses, and its inhibition may diminish D330012F22Rik activity. Y-27632, by inhibiting ROCK kinase involved in Rho signaling, can impact cytoskeletal arrangement and cellular contractility, which could decrease D330012F22Rik activity if the protein functions are related to these cellular processes. PP2 inhibits Src family kinases, and by doing so, it may reduce the activity of D330012F22Rik if the protein is a part of Src kinase signaling. Lastly, Chelerythrine and Bisindolylmaleimide I inhibit PKC, which could suppress D330012F22Rik activity by disrupting PKC-dependent signaling pathways, which are integral to numerous cellular functions including cell proliferation, differentiation, and apoptosis.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Inhibits AKT signaling, which is a pathway D330012F22Rik may be involved in, leading to decreased protein activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR signaling, potentially reducing the activity of D330012F22Rik involved in downstream signaling of this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that by inhibiting PI3K signaling could decrease the activity of D330012F22Rik linked to this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, which suppresses the PI3K/Akt pathway activity, potentially decreasing D330012F22Rik activity if it is linked to this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which is part of the MAPK/ERK pathway, and would decrease the activity of D330012F22Rik if it is regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK1/2 in the MAPK/ERK pathway, potentially reducing D330012F22Rik activity associated with this signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, which would decrease the activity of D330012F22Rik if it is part of the p38 MAPK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, decreasing the activity of D330012F22Rik that is part of or regulated by the JNK signaling pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK, which is involved in Rho signaling, potentially reducing D330012F22Rik activity if it is regulated by this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor that could decrease D330012F22Rik activity if the protein is involved in Src signaling. | ||||||